Physician profile
Wei Tang
NPI 1306232616
$3,099.03
in general payments reported to CMS, 2019-2025
35 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $68.62 · 2021: $349 · 2022: $472 · 2023: $417 · 2024: $770 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $891.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $270.19 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Amarin Pharma, INC. | $203.72 | 2019-2022 | |
| Amgen INC. | $177.28 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $119.42 | 2019-2024 | |
| Lilly USA, LLC | $109.21 | 2022-2025 | Kisunla, Jardiance, Amyvid |
| Ge Healthcare | $104.71 | 2023-2025 | |
| Sk Life Science, INC. | $99.50 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $95.86 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $92.64 | 2022-2025 | Rytary, Crexont |
| Merz Pharmaceuticals, LLC | $88.46 | 2024 | Xeomin |
| Inspire Medical Systems, INC. | $78.38 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.82 | 2019 | |
| Pfizer INC. | $65.91 | 2019-2024 | |
| Exact Sciences Corporation | $53.61 | 2024 | Cologuard Collection Kit |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.